Home » Topics » BioWorld Science

BioWorld Science
RSS

Progress in CNS drug development at Daiichi

Sep. 13, 1996

Chugai's CNS pipeline

Sep. 13, 1996

CNS research at Toyama

Sep. 13, 1996

Antioxidants isolated by Japanese researchers

Sep. 13, 1996

Neuronal calcium channel antagonists for stroke

Sep. 13, 1996

New cholinergic channel activators described by Abbott

Sep. 13, 1996

Inhibitors of C1r for Alzheimer's disease

Sep. 13, 1996

Lilly reports new treatment for attention deficit/hyperactivity disorder

Sep. 13, 1996

Hoechst Marion Roussel claims compound for neurodegenerative disorders

Sep. 13, 1996

Side effects of botulinum toxin A in the treatment of craniocervical dystonias

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...